AFTD currently has six active research funding programs to support FTD research at all stages, from discovery research to clinical trials. The newest of these programs is the FTD Diagnostic Biomarkers Initiative, based on the urgent need for early and accurate diagnosis. This program is generously supported by the AFTD Holloway Family Fund, the Alzheimer’s Association, the Rainwater Charitable Foundation, and the Robertson Foundation. Please join us in congratulating three new grantees, whose proposals cover the detection of disease in biofluids:

	Nicolas Barthélemy, PhD, Washington University, “Tau Citrullination in Biofluids as a Diagnostic Biomarker for Tauopathies”
	Andrew Stern, MD, PhD, Brigham and Women’s Hospital, “Detection of misfolded TDP-43 in FTD patient biofluids”
	Leonard Petrucelli, PhD, Mayo Clinic Jacksonville, “TDP-43 cryptic targets in FTD”